Navigation Links
YM BioSciences announces AACR acceptance of two nimotuzumab poster presentations
Date:3/15/2010

will be presented on Tuesday April 20, from 2-5pm in Exhibit Hall A-C, Poster section 27 by Aisha Fasih, a scientist from the laboratory of Dr. Raymond Reilly, Professor, Leslie Dan Faculty of Pharmacy at the University of Toronto.

"We continue to build upon our knowledge of the cancer-targeting attributes of nimotuzumab which contrast sharply with other approved EGFR-targeting antibodies in that nimotuzumab is selective for cancer cells, thereby minimizing toxicity while preserving efficacy," said David Allan, Chairman & CEO of YM BioSciences Inc. "In addition to greatly improving tolerability, we believe that this property uniquely positions our EGFR-targeting molecule for safe delivery of potent anticancer agents when conjugated to nimotuzumab. This presentation by scientists from the University of Toronto again demonstrates nimotuzumab as an antibody selectively targeting cancer cells overexpressing EGFR and points to the potential of nimotuzumab to safely deliver toxic payloads despite ubiquitous expression of EGFR in normal tissues."

"We are very much looking forward to presenting the results of these studies with 111In-NLS-nimotuzumab to the broader cancer research community at the upcoming AACR meeting," said Professor Raymond Reilly. "This is an excellent opportunity for us to describe our innovative
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2014)... September 12, 2014 Advancing the ... decontamination of chemical and biological threats is the ... Worcester Polytechnic Institute (WPI) and the Georgian National ... Science for Peace and Security Programme of the ... NATO’s Advanced Research Workshop series, the event is ...
(Date:9/12/2014)... Sandia Biotech, Inc. announced today that ... STC.UNM (STC) for a technology developed by researchers at ... Mexico, and Queen Mary University of London in London, ... Fluorescent Antibody Technology Platform (RFAP) was developed by Dr. ... Dr. Angray Kang from Queen Mary’s Department of Molecular ...
(Date:9/11/2014)... are first to show the use of sound to ... phenomena from quantum physics with sound taking on the ... the journal Science . , The interaction between ... studied extensively in the field of quantum optics. However, ... waves has been a more challenging undertaking. The Chalmers ...
(Date:9/11/2014)... , Sept. 11, 2014  Lakewood-Amedex ... pharmaceuticals, announced today that the United States ... ,Notice of Allowance, for patent application 11/673,486 ...  The ,486 patent application relates to the ... gene-silencing and can be designed to treat ...
Breaking Biology Technology:Worcester Polytechnic Institute to Lead Scientific Workshop on Nanoscale Defenses for Biological and Chemical Threats 2Worcester Polytechnic Institute to Lead Scientific Workshop on Nanoscale Defenses for Biological and Chemical Threats 3Sandia Biotech and STC.UNM Announce Option Agreement to License Novel Recombinant Antibody Technology 2Sandia Biotech and STC.UNM Announce Option Agreement to License Novel Recombinant Antibody Technology 3Sandia Biotech and STC.UNM Announce Option Agreement to License Novel Recombinant Antibody Technology 4The sound of an atom has been captured 2Lakewood-Amedex Receives Notice Of Allowance From The United States Patent and Trademark Office (USPTO) For A New Patent Covering Its nanoRNA Gene-Silencing Technology 2Lakewood-Amedex Receives Notice Of Allowance From The United States Patent and Trademark Office (USPTO) For A New Patent Covering Its nanoRNA Gene-Silencing Technology 3
... Sept. 1 Mylan Inc. (Nasdaq: MYL ... CEO of Trident USA Health Services, the nation,s largest ... long-term care industry, has joined Mylan,s Board of Directors. ... also is president of the International Federation of Pharmaceutical ...
... Sept. 1 /PRNewswire-FirstCall/ - avVaa World Health Care Products ... and distributor of nationally branded therapeutic, natural skin and ... its first week of DRTV 120/60 second test commercials ... COO of avVaa World Health Care Products Inc. stated, ...
... CITY, Sept. 1 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: ... global biopharmaceutical company focused on endocrine therapy and oncology, ... Medical Officer, Paul Blake, M.D., will present a corporate ... Global Investment Conference on Wednesday, September 9, 2009 at ...
Cached Biology Technology:Mark W. Parrish Joins Mylan's Board of Directors 2avVaa World Health Care Products, Inc. Announces the completion of its first week of DRTV 120/60 second test commercials for Neuroskin(R) Psoriasis Relief 2
(Date:9/12/2014)... College of New York biologist Mike Hickerson, a team of ... how so many species of birds ended up in the ... to the southernmost tip of South America. It is home ... question has beenhow did this extraordinary bird diversity originate?" said ... subject published in the journal Nature this week ...
(Date:9/12/2014)... cartilage plays an active role in the destruction ... rather than being an ,innocent bystander, as previously ... Dr Kate Lawler, Dr Ben Croker and colleagues ... the discovery while investigating the role of the ... The study was published in the journal ...
(Date:9/11/2014)... The classical treatise "Flora of Northumberland and Durham" ... Advanced Books platform as an example of ... create a new sort of resource and data re-use. ... botany of the region, which can be seen as ... on-line semantically enriched re-publication marries the meticulous detail ...
Breaking Biology News(10 mins):No innocent bystander: Cartilage contributes to arthritis 2Re-publication of 'Flora of Northumberland and Durham' (1831): A dramatic account of change 2Re-publication of 'Flora of Northumberland and Durham' (1831): A dramatic account of change 3
... Discovery Fund (LSDF) today announced $1.1 million in ... and non-profit organizations to foster the translation of ... marketplace. Two of the five new ... invented within Washington-based companies. HeatFlow Technologies (principal investigator ...
... Researchers at Queen Mary University of London have shown for ... on to perform is controlled by primary cilia tiny hair-like ... of becoming any cell type within the body through the ... for application in the development of new therapies for a ...
... has known for years that people who drink moderate amounts ... general, they are healthier and have better cardiovascular function that ... research from Oregon Health & Science University adds a fascinating ... help it fight off infection. The research, published Dec. ...
Cached Biology News:Life Sciences Discovery Fund announces R&D grants 2Study: Moderate alcohol consumption boosts body's immune system 2Study: Moderate alcohol consumption boosts body's immune system 3
... 'Agilents GeneSpring Workgroup solution is ... managing and mining expression data in ... and is deployed in over 40 ... research organizations worldwide. GeneSpring Workgroup streamlines ...
... Best: DASGIPs Process Control integrates Process ... comprehensive documentation for cultivation processes. A ... pH, dissolved oxygen, temperature and agitation ... Profiles, e.g. constant or scheduled media ...
... a genome-wide microRNA (miRNA) expression profiling service ... which enable highly sensitive and specific direct ... arrays for mature miRNA of all species ... Sanger miRBase database (Release 8.2). Our service ...
... PEP-165 is an 18 amino acid synthetic peptide whose sequences are ... is (amino to carboxy terminus): S(21) - S - M - ... - E - A - I - D - K - ... This peptide may be used for neutralization and control ...
Biology Products: